News

Details

Published: 21 June 2019

• portfolio-news

Confo Therapeutics today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the Company’s proprietary pre-clinical programs, targeting a neurological orphan indication. The grant will also support translational biology work by Confo alongside the teams of Prof Patrik Verstreken (VIB-KU Leuven Center for Brain & Disease Research), Prof Peter de Witte (Molecular Biodiscovery, KU Leuven) and Prof Guy Bormans (Radiopharmaceutical Research, KU Leuven).

Details

Published: 04 June 2019

• portfolio-news

Themis and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a second partnering agreement under which CEPI, with support from the EU’s Horizon 2020 programme, will provide up to US$21 million of non-dilutive capital for Themis’ Phase 3-ready Chikungunya vaccine (MV-CHIK). The funding will underwrite a collaborative effort to accelerate regulatory approval of Themis’ Chikungunya vaccine and ensure that at-risk populations have access to the vaccine. 

Details

Published: 28 May 2019

• portfolio-news

SNIPR BIOME today announced that the US Patent & Trademark Office has granted 2 patents covering concepts of shaping patients’ microbiomes to positively influence immuno-oncology therapies. The patents, US10,300,138 and US10,300,139 entitled “Selectively Altering Microbiota for Immune Modulation”, protect the modulation of anti-PD-1 and anti-PD-L1 immunotherapies using CRISPR, TALENs or any other guided nuclease to shape microbiota of patients.